The biotech company AGC Biologics is closing its facilities in Boulder and Longmont and is laying off a total of 267 employees in Colorado starting Nov. 15.
The company said in a notice to state and local officials Tuesday that it has restructured “in an effort to protect the longevity of the organization.” AGC Biologics will permanently lay off 218 employees in Boulder, 48 in Longmont and one in Kremmling. Eleven employees in other states who support the Colorado operations will also be let go.
The positions being eliminated include engineers and manufacturing jobs, according to the Worker Readjustment and Retraining Notification Act notice filed with the state.
AGC Biologics, a global company based in Bothell, Wash., has locations in Seattle as well as Germany, Italy, Japan and Denmark. In 2020, the company announced it had acquired AstraZeneca’s 300,000-square-foot facility in Boulder to revive manufacturing there.
The Colorado Economic Development Commission approved a Job Growth Incentive Tax Credit potentially worth $6.4 million and a Strategic Fund incentive of $75,000. Boulder provided a local match of $75,000. The incentives were contingent on AGC bringing 280 net new jobs to Boulder over the next eight years.
Updated Sept. 17, 2025, at 3:37 p.m. to delete reference to trade publication story.
Originally Published:
